期刊文献+

重组凝血因子Ⅶ表达和合成机制的研究进展 被引量:2

Research advances of recombinant coagulation factor Ⅶ expression and synthesizing mechanism
下载PDF
导出
摘要 血友病是由于人体内缺乏相应凝血因子造成的凝血障碍,目前主要利用基因重组技术在不同细胞中表达重组凝血因子Ⅶ(Ⅶ因子)从而对血友患者出血进行治疗。为有效提高重组Ⅶ因子的产量及活性,已有研究者尝试利用不同真核表达系统合成重组Ⅶ因子,如BHK细胞、CHO细胞、昆虫细胞和鱼胚胎等。同时,不同外源功能性基因对重组Ⅶ因子活性和翻译后修饰对表达产量的影响也通过不同方法进行探究。本文从Ⅶ因子在凝血途径中的作用、重组表达重组Ⅶ因子和翻译后修饰对合成的影响3个方面对重组Ⅶ因子表达和合成机制研究进行了综述。 Haemophilia is caused by lack of coagulation factor VIII or IX in patients′blood with inadequate hemostasis.Currently recombinant coagulation factor VII(rFVII)produced in different cells is used against clini-cal bleeding of haemophilia patients.To enhance the production and activity of rFVII;some eukaryotic cells such as baby hamster kidney(BHK);Chinese hamster ovary(CHO);insect cell and fish embryo;were used to express rFVII.Meanwhile;the effect of functional gene on the activity of rFVII and the limitation of rFVII production caused by post-translational modification were investigated by different methods.The role of rFVII in hemostasis;synthesis of rFVII in different eukaryotic cells and impact on production of post-translational modification are reviewed in this article.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2015年第5期623-628,共6页 Journal of China Pharmaceutical University
基金 国家高技术研究发展计划(863计划)资助项目(No.2014AA021003)~~
关键词 重组凝血因子Ⅶ 血友病 凝血机制 哺乳动物细胞 翻译后修饰 recombinant coagulation factor VII hemophilia hemostasis mechanism mammalian cell post-transla-tional modification
  • 相关文献

参考文献37

  • 1Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting [ J ]. Science, 1964,145 ( 3638 ) : 1310 - 1312.
  • 2Hoffman M, Pawlinski R. Hemostasis: old system, new players, new directions[ J]. Thromb Res ,2014,133 ( Suppl 1 ) : $1 - $2.
  • 3Repke D,Gemmell CH,Guha A,et al. Hemophilia as a defect of the tissue factor pathway of blood coagulation : effect of factors VIII and IX on factor X activation in a continuous-flow reactor [ J ]. PNAS, 1990,87 ( 19 ) : 7623 - 7627.
  • 4Roberts HR, Monroe DM, Escobar MA. Current concepts of hemo- stasis-implications for therapy [ J ]. Anesthesiology, 2004, 100 (3) :722 -730.
  • 5Dijk K, Fischer K, Born JG, et al. Variability in clinical pheno- type of severe haemophilia:the role of the first joint bleed [ J 3. Haemophilia ,2005,11 (5) :438 - 443.
  • 6Hedner U, Lee C. First 20 years with recombinant FVIIa ( Novo- Seven) [ J ]. Haemophilia,2011,17 ( 1 ) : 172 - 182.
  • 7Coppola A, Di Capua M, Di Minno MND, et al. Treatment of hemophilia: a review of current advances and ongoing issues [ J ]. J Blood Med,2010 ,! :183 - 195.
  • 8Nilsson I, Hedner U, BjtMin G. Suppression of factor IX antibodyin hemophilia B by factor IX and cyclophosphamide [ J ]. Ann Intern Med, 1973,78( 1 ) :91 -95.
  • 9Hedner U, Nilsson I, Bergentz S. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo [ J ]. Thromb Haemost , 1976,35 (2) :386 - 395.
  • 10Hedner U, Nilsson I, Bergentz S. Studies on the thrombogenic activities in two prothrombin complex concentrates [ J ]. Thromb Haemost, 1979,42 (3) : 1022 - 1032.

同被引文献10

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部